InvestorsHub Logo
Followers 6
Posts 554
Boards Moderated 0
Alias Born 03/21/2017

Re: namtae post# 12807

Sunday, 10/29/2017 4:53:33 PM

Sunday, October 29, 2017 4:53:33 PM

Post# of 21373
Wrong again. Dude its not that hard.

You said:


Some evidence of efficacy can stretch from one extreme to the other




That is an incoherent statement. Some evidence of efficacy means exactly that--it does not stretch from one extreme to another.

Stop throwing out terms like RECIST, we are no where close to that kind of data. It's phase 1 no one is claiming we are at phase II or III readouts.

And relax about all the endpoint and data readout stuff. You can't even do statistics on a treatment group of 3 people. The statements made about Prolanta being synergistic with chemo was from some preclinical animal model. Oncolix is nowhere close to even doing that in humans.

The point is Redman has said there was some evidence of efficacy. That, you are right, is not some FDA qualified case report in the New England Journal of Medicine. It's just a comment to take at face value.

Everyone on this board would likely not be here if the converse "the drug made the patients worse or showed 0 evidence of efficacy" was true.

Redman will tell us more after ticker change.



Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.